About Tirzepatide & Semaglutide

Tirzepatide & Semaglutide are highly effective weight loss medications prescribed for weight management in individuals with a body mass index (BMI) of 30 or higher or above 27 if they have a weight-related condition. They are also used to help control blood sugar levels in adults with type 2 diabetes.

Tirezepatide (the molecule in Mounjaro® and Wegovy®) and Semaglutide (the molecule in Ozempic® and Wegovy®) are part of the family of GLP-1 agonists or glucagon-like peptide-1 receptor agonists. These medications mimic the action of the naturally occurring hormone GLP-1. GLP-1 is an incretin hormone that is released in response to food intake to help regulate glucose levels. GLP-1 agonists bind to and activate GLP-1 receptors, primarily in the pancreas and the brain.

In the pancreas, GLP-1 agonists stimulate insulin secretion from beta cells when blood glucose levels are elevated, which helps lower blood sugar. They also suppress glucagon release from alpha cells, reducing the liver's glucose production. This dual action is critical for controlling blood sugar levels, particularly in individuals with type 2 diabetes.

Additionally, GLP-1 agonists slow gastric emptying, which leads to a prolonged feeling of fullness after eating and reduced appetite, contributing to weight loss. In the brain, these agonists affect areas that regulate appetite and food intake, further promoting weight loss.

Beyond glucose control and weight management, GLP-1 agonists have been shown to reduce cardiovascular risk by improving heart function and reducing the risk of heart attack and stroke. They also have protective effects on the kidneys, making them beneficial for patients with diabetes-related kidney disease. Clinical studies have shown that Tizepatide and Semaglutide can reduce HbA1c levels, body weight, and fasting blood sugar. Additionally, they may lower the risk of heart disease and complications such as eye and kidney problems.

​

Tirzepatide & Semaglutide For Weight Management

This class of drugs is particularly noteworthy for their role in addressing type 2 diabetes and obesity, and they continue to be a subject of interest in clinical research for their potential in improving metabolic health.

​

For instance, clinical studies have shown that Tirzepatide, a dual GIP and GLP-1 receptor agonist, can lead to significant weight loss in individuals with obesity or overweight. The SURMOUNT-1 clinical trial, which evaluated Tirzepatide for weight management, reported the following results:​

·  0.5 mg weekly dose: Patients typically experienced an average weight loss of around 5-7% of their body weight.

·  1.0 mg weekly dose: Studies have indicated a weight loss of around 7-10% of body weight.

·  2.0 mg weekly dose: For those on higher doses, weight loss can be in the range of 10-15% of body weight.

​

These results represent a substantial weight loss compared to placebo and even other weight loss medications. The degree of weight loss observed with Semaglutide has been one of the most significant reported in clinical trials for anti-obesity medications to date.